S. aureus vaccine development

February 26, 2024

CARB-X global partnership headed toward developing an innovative vaccine against potentially deadly Staphylococcus aureus bacteria that could be a “game changer” in stemming antimicrobial resistance (AMR).

IBT Supports New Monoclonal Antibody Under Development to Combat Marburg Virus

IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services

S. aureus vaccine development

SUBSCRIBE HERE!

Subscribe to the IBT Bioservices Tech Talk list and receive periodic updates on industry news and IBT Bioservices products and services.

Fight the BDBV Outbreak: Shop Ready-to-ship Bundibugyo Reagents

New Products in stock! Proudly made in USA. Shop now!

REAGENTS

View All

IN VITRO Services

ANIMAL SERVICES

S. aureus vaccine development

Share This

CATEGORIES

RECENT POSTS

IBT Supports New Monoclonal Antibody Under Development to Combat Marburg Virus

IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services

S. aureus vaccine development

SUBSCRIBE HERE!

You may also like

Combating the 2026 Bundibugyo Outbreak: How IBT Bioservices Accelerates Vaccine and Therapeutic Development

Accelerating Flavivirus Therapeutics: Validated Assays from Discovery to Dose

Unmatched Precision: IBT’s Advanced ELISA Testing Capabilities to Support Clinical & Preclinical Development for Vaccines and Therapeutics

Company

Media